- Home
- ATXG vs DRMA Comparison
ATXG vs DRMA Comparison
Compare ATXG & DRMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATXG
- DRMA
- Stock Information
- Founded
- ATXG 2014
- DRMA 2014
- Country
- ATXG China
- DRMA United States
- Employees
- ATXG N/A
- DRMA N/A
- Industry
- ATXG Professional Services
- DRMA Biotechnology: Pharmaceutical Preparations
- Sector
- ATXG Consumer Discretionary
- DRMA Health Care
- Exchange
- ATXG Nasdaq
- DRMA Nasdaq
- Market Cap
- ATXG 3.8M
- DRMA 3.3M
- IPO Year
- ATXG N/A
- DRMA 2021
- Fundamental
- Price
- ATXG $0.94
- DRMA $4.20
- Analyst Decision
- ATXG
- DRMA Strong Buy
- Analyst Count
- ATXG 0
- DRMA 1
- Target Price
- ATXG N/A
- DRMA $10.00
- AVG Volume (30 Days)
- ATXG 977.6K
- DRMA 344.3K
- Earning Date
- ATXG 11-13-2025
- DRMA 11-12-2025
- Dividend Yield
- ATXG N/A
- DRMA N/A
- EPS Growth
- ATXG N/A
- DRMA N/A
- EPS
- ATXG N/A
- DRMA N/A
- Revenue
- ATXG $4,310,835.00
- DRMA N/A
- Revenue This Year
- ATXG N/A
- DRMA N/A
- Revenue Next Year
- ATXG N/A
- DRMA N/A
- P/E Ratio
- ATXG N/A
- DRMA N/A
- Revenue Growth
- ATXG N/A
- DRMA N/A
- 52 Week Low
- ATXG $0.36
- DRMA $3.83
- 52 Week High
- ATXG $1.86
- DRMA $23.70
- Technical
- Relative Strength Index (RSI)
- ATXG 51.17
- DRMA 43.56
- Support Level
- ATXG $0.90
- DRMA $3.91
- Resistance Level
- ATXG $1.08
- DRMA $4.44
- Average True Range (ATR)
- ATXG 0.12
- DRMA 0.42
- MACD
- ATXG -0.02
- DRMA -0.06
- Stochastic Oscillator
- ATXG 33.61
- DRMA 22.06
About ATXG Addentax Group Corp.
Addentax Group Corp is an investment holding company. The company through its operating subsidiaries functions in the following segments; Garment manufacturing; Logistics services; Property management and subleasing. It generates maximum revenue from the Logistics services segment which provides logistics services including storage, transportation, warehousing, handling, packaging, and order processing. It also provides customs declaration and tax clearance services to its customers who export goods overseas. Geographically, the company derives all of its revenue from China.
About DRMA Dermata Therapeutics Inc.
Dermata Therapeutics Inc is a late-stage medical dermatology company focused on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical skin diseases and aesthetic applications. Its two product candidates, XYNGARI (formerly known as DMT310) and DMT410, incorporate its proprietary, multifaceted, Spongilla technology to topically treat a variety of dermatological conditions. Its Spongilla technology platform will enable to development and formulation of singular and combination products that can target topical delivery of chemical compounds into the dermis for maximum treatment effect for a variety of inflammatory skin diseases. Dermata announced positive Phase 3 data from its STAR-1 clinical trial in March 2025.